Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short term Debt: 2016-2025

Historic Short term Debt for Myriad Genetics (MYGN) over the last 4 years, with Jun 2025 value amounting to $59.4 million.

  • Myriad Genetics' Short term Debt was N/A to $59.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $59.4 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2020, which is 8.82% down from last year.
  • Myriad Genetics' Short term Debt amounted to $59.4 million in Q2 2025, which was down 42.94% from $104.1 million recorded in Q2 2021.
  • In the past 5 years, Myriad Genetics' Short term Debt ranged from a high of $104.1 million in Q2 2021 and a low of $59.4 million during Q2 2025.
  • In the last 1 years, Myriad Genetics' Short term Debt had a median value of $59.4 million in 2025 and averaged $59.4 million.
  • Data for Myriad Genetics' Short term Debt shows a peak YoY spiked of 3,258.06% (in 2021) over the last 5 years.
  • Myriad Genetics' Short term Debt (Quarterly) stood at $104.1 million in 2021, then followed by $59.4 million in 2025.
  • Its last three reported values are $59.4 million in Q2 2025, $104.1 million for Q2 2021, and $3.3 million during Q3 2020.